Continuous infusions of arabinosyl cytosine in patients with neoplastic disease

A study was undertaken of the effects of continuous infusion of arabinosyl cytosine in a group of patients with advanced cancer. Initially all patients received the drug for 7 days. The dose was increased in successive patients. Megaloblastosis occurred with doses as low as 3 mg. per square meter per day for 7 days, although no other hematopoietic effects of consequence occurred at doses less than 30 mg. per square meter per day. Depressions of leukocytes and platelets after 7 days of 30 mg. per square meter of arabinosyl cytosine were comparable to those reported by Talley after a much greater total dose. Compression of the total dose of 210 mg. per square meter into 3% instead of 7 days resulted in hematopoietic depression equivalent in degree and timing to that noted after the 7 day course. Further decrease of the length of the infusion of 210 mg. per square meter to 1.75, 0.875, or 0.44 days significantly decreased the hematopOietic depressant effects although megaloblastosis was again seen in all. Gastrointestinal toxicity was minor with one week infusions but occurred more frequently when the same total dose was given over a shorter period of time. No therapeutic activity was seen during this study.

[1]  N. Mantel,et al.  Chemotherapy of leukemia L1210 in mice with 1-beta-D-arabinofuranosylcytosine hydrochloride. II. Effectiveness against intracerebrally and subcutaneously inoculated leukemic cells. , 1966, Cancer research.

[2]  D. R. Dubbs,et al.  Arabinofuranosylcytosine-induced stimulation of thymidine kinase and deoxycytidylic deaminase activities of mammalian cultures. , 1966, Cancer research.

[3]  M. Murphy,et al.  Cytosine arabinoside (NSC-63878) in acute leukemia in children. , 1966, Cancer chemotherapy reports.

[4]  C. G. Smith,et al.  Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. , 1967, Biochemical pharmacology.

[5]  Adamson Rh,et al.  Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC-63878). , 1965 .

[6]  S. Silagi.  Metabolism of 1-beta-D-arabinofuranosylcytosine in L cells. , 1965, Cancer research.

[7]  I. Wodinsky,et al.  Activity of cytosine arabinoside (NSC-63878) in a spectrum of rodent tumors. , 1965, Cancer chemotherapy reports.

[8]  F. Rapp,et al.  DIFFERENTIAL EFFECTS OF INHIBITORS ON THE STEPS LEADING TO THE FORMATION OF SV40 TUMOR AND VIRUS ANTIGENS , 1965, The Journal of experimental medicine.

[9]  M. Chu,et al.  COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE. , 1965, Biochemical pharmacology.

[10]  M. L. Eidinoff,et al.  ACTION OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE ON THE NUCLEIC ACID METABOLISM AND VIABILITY OF HELA CELLS. , 1965, Cancer research.

[11]  F. Rapp.  INHIBITION BY METABOLIC ANALOGUES OF PLAQUE FORMATION BY HERPES ZOSTER AND HERPES SIMPLEX VIRUSES. , 1964, Journal of immunology.

[12]  S. D. Weed,et al.  CYTOSINE ARABINOSIDE (CA) AND OTHER NUCLEOSIDES IN HERPES VIRUS INFECTIONS. , 1964, Archives of ophthalmology.

[13]  J. Evans,et al.  The Effect of 1-β-d-Arabinofuranosylcytosine Hydrochloride on Murine Neoplasms , 1964 .

[14]  L. Bostwick,et al.  SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN. , 1964, Biochemical pharmacology.

[15]  G. Mengel,et al.  THE REVERSAL OF CYTOSINE ARABINOSIDE ACTIVITY IN VIVO BY DEOXYCYTIDINE. , 1964, Biochemical pharmacology.

[16]  D. Buthala,et al.  Cell Culture Studies on Antiviral Agents , 1964, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  E. D. Maloney,et al.  IDU and cytosine arabinoside in experimental herpetic keratitis. , 1963, Archives of ophthalmology.

[18]  V. Vaitkevicius,et al.  Megaloblastosis produced by a cytosine antagonist, 1-beta-D-arabinofuranosylcytosine. , 1963, Blood.

[19]  M. Chu,et al.  A proposed mechanism of action of 1-beta-D-arabinofuranosyl-cytosine as an inhibitor of the growth of leukemic cells. , 1962, Biochemical pharmacology.

[20]  J. Evans,et al.  Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Hydrochloride , 1961 .

[21]  J. Burchenal,et al.  The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2'-deoxyuridine). , 1960, Cancer chemotherapy reports.

[22]  N. Mantel,et al.  Modification of treatment of schedules in the management of advanced mouse leukemia with amethopterin. , 1956, Journal of the National Cancer Institute.